Revolution Medicines CEO Mark A. Goldsmith reports disposal of common shares worth $16.87 million
RVMD•RVMD•RVMD•RVMD•Two revocable trusts reported small same-day sales, leaving 61,424 shares in each trust.
A separate revocable living trust reported 594,060 shares held indirectly.
Revolution Medicines CEO Mark A. Goldsmith exercised stock options for 80,000 shares at $4.73 on Aug. 21, 2026.
He sold 80,000 shares the same day in open-market transactions at weighted-average prices near $207.23 to $212.08.
Directly held common stock fell to 267,330 shares following the transactions.
